Excellent Response Rate to a Double Dose of the Combined Hepatitis A and B Vaccine in Previous Nonresponders to Hepatitis B Vaccine
|
|
- Molly Willis
- 5 years ago
- Views:
Transcription
1 MAJOR ARTICLE Excellent Response Rate to a Double Dose of the Combined Hepatitis A and B Vaccine in Previous Nonresponders to Hepatitis B Vaccine Kristina Cardell, 1 Britt Åkerlind, 2 Matti Sällberg, 3 and Aril Frydén 1 Departments of 1 Infectious Diseases and 2 Clinical Microbiology, University Hospital, Linköping, and 3 Division of Clinical Virology, Karolinska Institute at Karolinska University Hospital, Huddinge, Sweden (See the editorial commentary by Diepolder, on pages ) Background. Hepatitis B vaccine has been shown to be highly efficient in preventing hepatitis B. However, 5% 10% of individuals fail to develop protective levels ( 10 miu/ml) of antibodies to hepatitis B surface antigen (anti-hbs) and are considered to be nonresponders. Methods. A total of 48 nonresponders and 20 subjects naive to the HBV vaccine received a double dose of combined hepatitis A and B vaccine (Twinrix) at 0, 1, and 6 months. The levels of anti-hbs and antibodies to hepatitis A virus (anti-hav) were determined before vaccination and 1 month after each dose. Results. Among 44 nonresponders, protective anti-hbs levels were found in 26 (59%) after the first dose and in 42 (95%) after the third dose. Among the control subjects, the corresponding figures were 10% and 100%, respectively. All subjects seroconverted to anti-hav. The titers of both anti-hbs and anti-hav were lower in the previously nonresponsive subjects (P.01). Conclusion. Revaccination of nonresponders to the standard hepatitis B vaccine regimen with a double dose of the combined hepatitis A and B vaccine was highly effective. This is most likely explained by the increased dose, a positive bystander effect conferred by the hepatitis A vaccine, or both. Received 26 November 2007; accepted 28 February 2008; electronically published 10 June Potential conflicts of interest: none reported. Financial support: County of Östergötland, Sweden; Swedish Cancer Foundation (grant 3825B0712XCC to M.S.). Reprints or correspondence: Dr. Kristina Cardell, Dept. of Infectious Diseases, University Hospital, S Linköping, Sweden (Kristina.Cardell@lio.se). The Journal of Infectious Diseases 2008; 198: by the Infectious Diseases Society of America. All rights reserved /2008/ $15.00 DOI: / Hepatitis B virus (HBV) is widely spread, and 350 million people are estimated to be chronic carriers [1]. HBV can cause acute hepatitis, which in some cases leads to acute liver failure. Approximately 5% become chronic carriers and are at risk of developing liver cirrhosis and hepatocellular cancer. Transmission of HBV can be prevented by vaccination [2]. After immunization, a serum titer of antibodies to hepatitis B surface antigen (anti- HBs) of 10 miu/ml has been shown to be effective in preventing disease and is the generally accepted level for determining that a vaccine response has occurred [3]. Health care personnel are at risk of acquiring HBV infection, and many authorities recommend vaccination [4]. After a standard 3-dose vaccination regime at 0, 1, and 6 months, the rate of response on the basis of an anti-hbs titer of 10 miu/ml is 90% 95%. Intramuscular and intradermal administration has been reported to be equal in inducing seroconversion, but titers seem to be higher with intramuscular administration [5, 6]. A small portion of vaccinated individuals do not develop anti-hbs titers of 10 miu/ml after 3 or more doses and are considered to be nonresponders. Risk factors for nonresponse have been identified, including immunosuppressive disease, smoking, increasing age, male sex, and high body mass index (BMI) [6, 7]. Genetic factors also seem to play a role in the response [8 11]. Several methods to improve the response in nonresponders have been suggested, such as giving the vaccine intramuscularly to those previously vaccinated intradermally and vice versa [12 14]. Higher vaccine doses, adding adjuvant substances (such as granulocyte-macrophage colony-stimulating factor) [15, 16], and adding additional envelope protein (pres1 and pres2) [17] have also been studied. The results in inducing seroconversion in nonresponders have varied from 50% to 90% among different studies and different revaccination protocols Hepatitis Vaccine in Nonresponders JID 2008:198 (1 August) 299
2 [12 18]. In some smaller studies, a high response rate has been noted. In one study, nonresponders to intramuscular vaccine were vaccinated with repetitive intradermal doses every second week (with a maximum of 4 doses), and 17 (94%) of 18 responded to this regime [14]. In another study, 62 (89%) of 70 public safety workers who had been previously vaccinated intradermally responded after 3 additional doses of standard-dose intramuscular vaccine [12]. A higher vaccine dose is recommended in immunocompromised subjects, such as patients undergoing hemodialysis [19]. To protect individuals at high risk for hepatitis B exposure against becoming infected with HBV, there is a need for effective regimes that can make nonresponders respond to hepatitis B vaccine. The combined hepatitis A and B vaccine has been shown to be very effective in inducing seroconversion to both hepatitis A virus (HAV) and HBV in healthy vaccinees. [20]. Some studies have shown even higher anti-hav levels with the combined vaccine than with the monovalent vaccine in healthy adults [21], whereas other studies have not been able to show this [22, 23]. The aim of the present study was (1) to see whether a high dose of hepatitis B antigen, normally used for immunocompromised patients, in combination with hepatitis A vaccine could induce protective anti-hbs titers ( 10 miu/ml) in healthy nonresponders to hepatitis B vaccine and (2) to investigate the humoral immune response to hepatitis B vaccine in nonresponders, compared with that in vaccine-naive individuals. METHODS Subjects. Health care workers known to be nonresponders to hepatitis B vaccine were asked to participate in a prospective study. Participants were chosen from a group of vaccinees who had participated in a previous study of intradermal hepatitis B vaccine given at 0, 1, and 6 months in the Department of Infectious Diseases, University Hospital, Linköping, Sweden. All vaccinees in the previous study had been vaccinated by 2 nurses who had vast experience with intradermal immunization. Nonresponders were defined as those who had received at least 4 doses of recombinant hepatitis B vaccine (Engerix-B; 0.1 ml intradermally; GlaxoSmithKline) without developing anti-hbs titers of 10 miu/ml; after measurement of anti-hbs, all had received a forth dose followed by new anti-hbs testing, which still showed anti-hbs titers of 10 miu/ml. All participants received oral and written study information, and all gave oral informed consent for participation in the study. Healthy adults who were 18 years of age and seronegative for HAV and HBV were chosen from people who contacted the department for vaccination to serve as the reference group. The reference group consisted mainly of health care workers and students in health care science. Exclusion criteria for the study were the presence of serious diseases affecting the immune system and pregnancy. All were negative for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen, anti-hbs, and anti-hav before inclusion. All subjects in the study were vaccinated intramuscularly at 0, 1, and 6 months with 2.0 ml of combined hepatitis A and B vaccine (Twinrix; GlaxoSmithKline) at the Department of Infectious Diseases, University Hospital, Linköping. Blood samples were drawn 5 times during the study period: before the first dose, immediately before the second dose, 1 month after the second dose, immediately before the third dose, and 1 month after the third dose. Adverse events were registered in a questionnaire administered after each dose; additionally, nurses inquired about adverse events each time a sample was drawn and before each new dose. The study was approved by the Ethics Committee of the Health University, Linköping, Sweden. Methods of virological serology. All testing of HBV markers were performed at the clinical microbiology laboratory of University Hospital, Linköping. Measurement of anti-hbs levels was done using the AxSYM AUSAB assay (Abbott Laboratories). Samples with anti-hbs concentrations reported as 1000 miu/ml were diluted using the automated dilution protocol. Samples with anti-hbs concentrations reported as 25,000 miu/ml by the automated dilution protocol were diluted using a manual dilution of 1:25. The amount of anti-hbs in samples was determined using a calibration curve. Measurement of anti- HAV levels was done using the AxSYM HAVAB 2.0 quantitative assay (Abbott Laboratories). The dynamic range of this assay is miu/ml. For anti-hav levels of 100 miu/ml, a standard dilution protocol described by the manufacturer was used. For anti-hav levels of 20,000 miu/ml, no further dilution protocol existed. Therefore, no further dilution was done. These titers are referred to as 20,000 miu/ml in the statistical analyses. Statistical analyses. The study was designed as an open trial. We estimated that, with a study group of 50 nonresponders and a reference group of 20 previously unvaccinated healthy individuals, we would be able to answer our questions that is, we would be able to show differences between the groups (but not similarities), and the reference group would show whether the vaccination schedule would work in a normal population. Differences in demographic data between the groups were analyzed by t test. For comparing titers after each dose, the Mann- Whitney rank-sum test was used; for response rates after each dose, Fisher s exact test was used. We also analyzed the influence of such cofactors as smoking, age, BMI, and sex on the results. For this analysis, we used a general linear model. The model was selected by beginning with a full model that included all interactions allowed by the data; then reducing interactions, starting from highest order stepwise; and then reducing the main effects if they were not part of the interactions. For anti-hbs titers, we choose to do the calculations with logarithmic data, because of the wide variation in levels and because the effect for anti-hbs seemed to be multiplicative rather than additional; we used numeric values for anti-hav titers. Correlation between log anti- HBs and anti-hav titers after 3 doses was measured. The 300 JID 2008:198 (1 August) Cardell et al.
3 Table 1. Summary of demographic data. Group Sex, no. male/female Age, mean (range), years BMI, mean (range) Smoking, no. Nonresponders 5/39 50 (21 69) 25.5 ( ) 13 Reference group 2/18 34 (20 59) 24.4 ( ) 1 P NOTE. BMI, body mass index. Minitab software package (version 13) was used for the statistical analyses. RESULTS Patient demographics. A total of 48 nonresponders were enrolled, of whom 44 completed the study. Of the 4 who did not complete it, 1 moved abroad during the study period, 1 did not show up for further vaccination for unknown reasons, 1 was impossible to evaluate because the subject s blood samples were accidentally misplaced in the laboratory, and 1 experienced severe tiredness after the first dose and did not receive any further doses (this occurrence was reported to the Swedish Medical Products Agency, which concluded that it could have been a vaccine-related adverse event). Twenty healthy HAV- and HBVnonimmune adults were enrolled in the reference group, all of whom completed the study. Apart from the tiredness described above, no serious adverse events were seen in either the nonresponder group or the reference group. Demographic data are shown in table 1. Because all of the subjects in the nonresponder group and the majority of those in the reference group were either health care workers or students in health care science, there was an overrepresentation of women in this study (reflecting that more women than men work in health care). In the nonresponder group, 13 subjects were smokers, 1 had stopped smoking immediately before inclusion, and an additional 4 had stopped 4 5 years before entering the study. The corresponding figures for the reference group were 1 smoker and 2 previous smokers. For 2 persons in the nonresponder group and 1 in the reference group, smoking data were not available. Mean BMI was higher in the nonresponder group (mean, 25.5; range, ) than in the reference group (mean, 24.4; range, ), as was the mean age (50 [range, 21 69] years in the nonresponder group vs. 34 [range, 20 59] years in the reference group) (P.001 for both comparsions). Antibody responses. Of the 44 nonresponders who completed the study, 26 (59%), 35 (80%), and 42 (95%) developed anti- HBs levels of 10 miu/ml after the first dose, the second dose, and the complete 3-dose schedule, respectively. In the reference group, the corresponding figures were 2 (10%) of 20, 19 (95%) of 20, and 20 (100%) of 20, respectively (figure 1). Of the 2 nonresponders, 1 did not have a detectable anti-hbs level, and 1 had an anti-hbs level of 8.5 miu/ml. Both of these individuals were smokers. After 3 doses, a total of 35 nonresponders (80%) developed anti-hbs titers of 100 IU/mL. All subjects in the reference group had an anti-hbs titer of 100 IU/mL after 3 doses. All subjects in both groups responded to hepatitis A vaccine and developed anti-hav. Taken together, these data indicate that previous nonresponders show an anamnestic response to revaccination, given that significantly more subjects developed protective anti-hbs levels after the first injection (26/44 [59%] vs. 2/20 [10%]; P.001,Fisher s exact test). Thus, despite the absence of protective levels of anti-hbs from the previous vaccination, the immune systems of these subjects were primed to HBsAg, suggesting that they may, in fact, have been protected against infection. The present revaccination schedule was highly effective in inducing seroconversion, given that there was no statistical difference in frequency after 3 doses (42/44 vs. 20/20; difference not significant). However, anti-hbs as well as anti-hav levels were significantly lower in the nonresponder group than in the reference group (P.001 and P.001, respectively). This suggests that nonresponder status with respect to HBsAg may not be an isolated immunological event but rather reflect a more general phenomenon. Anti-HAV and anti- HBs levels after each dose for all individuals are shown in figures 2 and 3, respectively, with the median marked for all doses and groups. Figure 1. No. of vaccinees who achieved a protective level ( 10 miu/ml) of antibodies to hepatitis B surface antigen (anti-hbs) after each dose in the nonresponder group and in the reference group. P values for differences in the response rate between the 2 groups are given (Fisher s exact test). Hepatitis Vaccine in Nonresponders JID 2008:198 (1 August) 301
4 Figure 2. Levels of antibodies to hepatitis A virus (HAV) after each dose in the nonresponder group and in the reference group. Lines indicate medians. The difference in anti-hav level between the reference group and the nonresponder group after 3 doses was statistically significant (P.001, Mann-Whitney rank-sum test). When analyzing the influence of other factors known to correlate with the rate of response to a complete hepatitis B vaccination schedule by use of a general linear model, we found that both a high BMI (P.001) and smoking (P.004) were associated with lower anti-hbs levels and that a high BMI was associated with lower anti-hav levels (P.016). The effect of these factors seemed to be more pronounced in the nonresponder group than in the reference group for both anti-hbs and anti-hav. A correlation between anti-hbs and anti-hav titers after 3 doses was found, with a correlation coefficient of for log anti-hbs and anti-hav titers (P.001). DISCUSSION The absence of protective levels of antibodies (i.e., nonresponder status) after hepatitis B vaccination is a clinical problem, and 302 JID 2008:198 (1 August) Cardell et al. Figure 3. Levels of antibodies to hepatitis B surface antigen (antihbs) after each dose in the nonresponder group and in the reference group. Lines indicate medians. P values for differences in anti-hbs level after each dose between the 2 groups are given (Mann-Whitney ranksum test). several methods to correct it have been tested [12 18]. In the present study, we used a high dose of the combined hepatitis A and B vaccine and obtained an excellent seroconversion rate (95%) among nonresponders. Other studies have shown similarly high response rates. In one study, intradermally vaccinated nonresponders were inoculated with 3 doses of intramuscular vaccine, and a response rate of 89% was achieved; however, nonresponders in this study had received only 3 doses of intradermal vaccine, and only 49% were primary responders [12]. In another study, repetitive intradermal doses were given as described above to nonresponders to at least 5 doses of hepatitis B vaccine, and 94% responded [14]. One could conclude from these studies and from our present data that the response seems to be dose dependent. We also found that 59% of the nonresponders developed a protective anti-hbs level after the first dose, compared with only 10% in the reference group. This strongly suggests that the immune system of nonresponders was primed by the previous round of vaccination. Subsequently, some or most nonre-
5 sponders might actually be protected against hepatitis B despite the absence of protective anti-hbs levels, consistent with previous observations [24]. Only 2 of the nonresponders failed to produce protective levels of anti-hbs, and of these only 1 was completely negative for anti-hbs, suggesting a true nonresponder status. Thus, true nonresponder status seems to be quite rare, whereas most subjects who fail to respond to the first round of hepatitis B vaccination are merely poor responders. In the present study, we also confirmed the effects of previously noted factors predisposing to nonresponder status. For example, both of the nonresponders who failed to respond to revaccination were smokers. However, many others had this risk factor, suggesting that smoking alone cannot explain their poor anti-hbs responses. Other known risk factors for nonresponder status seemed to affect the anti-hbs titers to a greater degree in the nonresponder group than in the reference group, indicating that other factors, such as genotype, could influence the results. Our results suggest that a high dose of HBsAg in combination with the hepatitis A antigen could offer a clinically relevant approach to correcting nonresponder status in persons who are not already immune to hepatitis A and for whom protection against hepatitis B is essential. It has been shown that, in healthy individuals, anti-hbs levels are higher when the combined vaccine is used than when a vaccine containing HBsAg alone is used [25]. It is therefore likely that, with the combined hepatitis A and B vaccine (Twinrix), the hepatitis A component might act as an adjuvant for the hepatitis B response. Our present data certainly favor this hypothesis. Titers are of less importance according to present consensus recommendations, which state that once the titer reaches 10 miu/ml there is no need for further testing or booster doses in immunologically competent persons [26]. A potentially important observation was that both anti-hbs and anti-hav titers were significantly lower in the nonresponder group than in the reference group. This would imply that nonresponder status after the first round of hepatitis B vaccination reflects a more general inability to rapidly generate high levels of antibodies in response to vaccination. Our findings suggest that, in these individuals, the reduced ability to respond to hepatitis B vaccine could be associated with a generally reduced capacity to produce vaccine-induced antibodies. To test this hypothesis, it would be of interest to investigate whether nonresponders or low responders to hepatitis B vaccine also have poor response to other vaccine antigens after immunization. Another explanation for the reduced levels of both anti-hbs and anti- HAV in the nonresponder group could be that, whereas the hepatitis A component acts as an adjuvant to the hepatitis B response, the hepatitis B antigen (or immune response) had a negative effect on the hepatitis A response. Additional studies are needed to elucidate this issue. In conclusion, in light of the present results, we propose that a double dose of the combined hepatitis A and B vaccine can be safely and effectively used to induce protective levels of anti-hbs in nonresponders to the traditional hepatitis B vaccine among those nonimmune to hepatitis A. Acknowledgments Vaccine was supplied by GlaxoSmithKline. Liselott Lindvall and Kerstin Samuelsson, nurses in the Department of Infectious Diseases, performed vaccination and collected blood samples. Inga-Lill Lundin, technician in the Department of Clinical Microbiology, analyzed all samples for serological data. References 1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999; 179: Centers for Disease Control. Protection against viral hepatitis: recommendations of the Immunization Practises Advisory Committee (ACIP). MMWR Recomm Rep 1990; 39: Payton CD, Scarisbrick DA, Sikotra S, Flower AJE. Vaccination against hepatitis B: comparison of intradermal and intramuscular administration of plasma derived and recombinant vaccines. Epidemiol Infect 1993; 110: Struve J, Aronsson B, Frenning B, Granath F, von Sydow M, Weiland O. Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. Scand J Infect Dis 1992; 24: Cardell K, Frydén A, Normann B. Intradermal hepatitis B vaccination in health care workers: response rate and experiences from vaccination in clinical practise. Scand J Infect Dis 1999; 31: Alper C, Kruskall M, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B Vaccine. N Engl J Med 1989; 321: Höhler T, Reuss E, Evers N, et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 2002; 360: Kruger A, Adams P, Hammer J, et al. Hepatitis B surface antigen presentation and HLA-DRB1* lessons from twins and peptide binding studies. Clin Exp Immunol 2005; 140: Langö-Warensjö A, Cardell K, Lindblom B. Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Tissue Antigens 1998; 52: Pegues DA, Woodruff BA, Lambert SB, Tant MK, Woernle CH. Immune response to intramuscular revaccination after primary intradermal vaccination against hepatitis B. Clin Infect Dis 1995; 20: Levitz RE, Cooper BW, Regan HC. Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. Infect Control Hosp Epidemiol 1995; 16: Playford EG, Hogan PG, Bansal AS, et al. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 2002; 23: Kim Myong-Jin, Nafzinger AN, Harro Clayton D, et el. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 2003; 21: Hasan MS, Agosti JM, Reynolds KK, et al. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. J Infect Dis 1999; 180: Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 1997; 314: Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Seroconversion after additional vaccine doses to nonresponders to three doses of Hepatitis Vaccine in Nonresponders JID 2008:198 (1 August) 303
6 intradermally or intramuscularly administered recombinant hepatitis B vaccine. Scand J Infect Dis 1994; 26: Centers for Disease Control and Prevention. Recommendations for preventing transmissions of infectious diseases among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50: Thoelen S, Van Damme P, Leentvaar-Kuypers A, et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 1999; 17: Czeschinski PA, Binding N, Witting U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. Vaccine 2000; 18: Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 2003; 21: Stoffel M, Lievens M, Dieussaert I, Martin I, Andre F. Immunogenicity of Twinrix in older adults: a critical analysis. Expert Rev Vaccines 2003; 2: Jarrosson L, Kolopp-Sarda MN, Aguilar P, et al. Most humoral nonresponders to hepatitis B vaccines develop HBV-specific cellular immune responses. Vaccine 2004; 22: Rieger MA, Hofmann F, Michaelis M. Simultaneous vaccination against hepatitis A and B: results of an open, randomized study from the occupational health point of view. Int J Occup Med Environ Health 2004; 17: European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: JID 2008:198 (1 August) Cardell et al.
subjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGuideline on the use of Hepatitis A&B Immunisations for Immunocompromised and Immunocompetent Hepatology Patients
Guideline on the use of Hepatitis A&B Immunisations for Immunocompromised and Immunocompetent Hepatology Patients WOMEN AND CHILDREN S DIRECTORATE ACUTE SERVICES DIVISION GUIDELINES TITLE Guideline on
More informationFor the additional vaccination phase
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAre booster immunisations needed for lifelong hepatitis B immunity?
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity, following meeting in Florence in October 1998 To date there are no data to support
More informationSynopsis of study HBV-314 BST 280 (108988)
Synopsis of study HBV-314 BST 280 (108988) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011
Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine
More information9/12/2018. Hepatitis B Virus Infection. Hepatitis B Infection
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Hepatitis B and Hepatitis B Vaccine Adult Track Chapter 10 Photographs and images included in this presentation
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationHepatitis A and B Booster Recommendations: Implications for Travelers
TRAVEL MEDICINE Charles D. Ericsson, Section Editor INVITED ARTICLE Hepatitis A and B Booster Recommendations: Implications for Travelers Jane N. Zuckerman, 1,2 Bradley A. Connor, 3,4 and Frank von Sonnenburg
More information2018 Adult Immunization Schedule
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases 2018 Adult Immunization Schedule National Adult Immunization Coordinators Partnership Quarterly Meeting
More informationOUR EXPERIENCE IN PREVENTION BY SELECTIVE IMMUNIZATION AGAINST VIRAL HEPATITIS A AND B OF THE STAFF OF MILITARY MEDICAL ACADEMY BULGARIA.
OUR EXPERIENCE IN PREVENTION BY SELECTIVE IMMUNIZATION AGAINST VIRAL HEPATITIS A AND B OF THE STAFF OF MILITARY MEDICAL ACADEMY BULGARIA. Col. GALEV Andrey MD PhD, KOVALYOVA Valentina, MD, PhD, Maj. KANEV
More informationORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university
Malaysian J Pathol 2018; 40(3) : 295 302 ORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university Siti Norlia OTHMAN, Zetti ZAINOL
More informationEvaluation of Hepatitis B Vaccination Efficiency among Health Care Workers in West of Iran. Farajolah Maleki 2 **
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2017, 9 [5]:29-34 [http://scholarsresearchlibrary.com/archive.html] ISSN 0975-5071 USA CODEN: DPLEB4
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 6 To provide guidelines for administering immunizations. PURPOSE POLICY Immunizations are to be administered to all patients in accordance with the North Carolina Immunization Regulations and
More informationEvidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand
Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand http://waipra.blogspot.com/2011/02/9.html Burden of disease in Thailand Liver diseases
More informationImmunologic Response to Hepatitis B Vaccine in Health Care Workers: A Screening Program and Evaluation of Some Host-Related Factors Role
American Journal of Immunology 7 (1): 12-16, 2011 ISSN 1553-619X 2011 Science Publications Immunologic Response to Hepatitis B Vaccine in Health Care Workers: A Screening Program and Evaluation of Some
More informationWashtenaw County Community Mental Health HEALTH CARE PERSONNEL (HCP) VACCINES (RECOMMENDED EMPLOYEE IMMUNIZATIONS)
Washtenaw County Community Mental Health HEALTH CARE PERSONNEL (HCP) VACCINES (RECOMMENDED EMPLOYEE IMMUNIZATIONS) PURPOSE To reduce the risk of exposure of Washtenaw County Community Mental Health (CMH)
More informationIMMUNOGENICITY OF PLASMA DERIVED V ACCINE IN ETHIOPIAN HOSPITAL PERSONNEL. Hailu Kefenie.,MD, Bekure Des!A. & Almaz Abebe..,MSc
IMMUNOGENICITY OF PLASMA DERIVED V ACCINE IN ETHIOPIAN HOSPITAL PERSONNEL Hailu Kefenie.,MD, Bekure Des!A. & Almaz Abebe..,MSc ABSTRACT: To study the immunogenicity of plasma derived hepatitis B vaccine,
More informationHepatitis B. Data from the Travel Health Surveillance Section of the Health Protection Agency Communicable Disease Surveillance Centre
Hepatitis B Introduction Hepatitis B virus is one of the most prevalent viruses worldwide and is a major cause of chronic liver disease and hepatocellular carcinoma. It is a hepadnavirus, consisting of
More informationThe Use of a Combination Vaccine in International Travelers Visiting Countries with High Endemic Rates of Hepatitis A and/or Hepatitis B
American Journal of Infectious Diseases 4(2): 104-108, 2008 ISSN 1553-6203 2008 Science Publications The Use of a Combination Vaccine in International Travelers Visiting Countries with High Endemic Rates
More information494 La Revue de Santé de la Méditerranée orientale, Vol. 11, N o 3, 2005
494 La Revue de Santé de la Méditerranée orientale, Vol. 11, N o 3, 2005 Short communication Hepatitis B surface antibody response of household contacts of hepatitis B virus carriers in Palestine K. Adwan,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationResearch Article Decrease in Anti-HBs Antibodies over Time in Medical Students and Healthcare Workers after Hepatitis B Vaccination
Hindawi BioMed Research International Volume 2017, Article ID 1327492, 5 pages https://doi.org/10.1155/2017/1327492 Research Article Decrease in Anti-HBs Antibodies over Time in Medical Students and Healthcare
More informationSelected Primary-Care Issues in HIV Disease
Perspective Selected Primary-Care Issues in HIV Disease Primary care for HIV-infected patients includes ensuring that eligible patients receive hepatitis B and A virus vaccinations, all women undergo appropriate
More informationHepatitis B is a serious infectious disease causing
Commentaries Hepatitis B Immunization in Health Care Workers Dealing with Vaccine Nonresponse Gregory A. Poland, MD Hepatitis B is a serious infectious disease causing substantial morbidity and mortality.
More informationHost Genetics of Response to Hepatitis B Vaccine: A Systematic Review
Mémoire de Maîtrise en médecine No 1488 Host Genetics of Response to Hepatitis B Vaccine: A Systematic Review Student Benoît Delabays Tutor PD Dr Pierre-Yves Bochud Service des maladies infectieuses Département
More informationVaccine preventable health associated infections (HAI) Entesar Husain BM BCH, FRCPC
Vaccine preventable health associated infections (HAI) Entesar Husain BM BCH, FRCPC Assistant Professor, Department of Pediatrics Faculty of Medicine Consultant Pediatric Infectious Diseases NBK Hospital
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationImmunization Update 2018
Immunization Update 2018 Keri Hurley-Kim, PharmD, MPH Assistant Professor, Department of Pharmacy Practice West Coast University School of Pharmacy Conflicts of Interest Keri Hurley-Kim declares no conflicts
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationSeroprevalence of Hepatitis B Infection among Health Care Workers and the Importance of Anti HBs Testing among the Health Care Workers
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 2280-2285 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.270
More informationImmunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients
Kidney International, Vol. 68 (2005), pp. 2298 2303 Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients NORELLA KONG CHIEW TONG,JIRI BERAN,SWEE
More informationSeroprotection after Hepatitis B Vaccination among Newborn Infants: a Review
Center for Global Health Seroprotection after Hepatitis B Vaccination among Newborn Infants: a Review Rania Tohme, MD, MPH Team Lead Global Immunization Division, US CDC Viral Hepatitis Prevention Board
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationHEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011
HEPATITIS B INFECTION and Pregnancy Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011 HEPATITIS B 26/07/2011 What is Hepatitis B? It is inflammation (infection) of the liver
More informationKalagara Pavani*, Srinivas Rao MS, Vinayaraj EV, Manick Dass
International Journal of Research in Medical Sciences Pavani K et al. Int J Res Med Sci. 2015 Mar;3(3):583-587 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: 10.5455/2320-6012.ijrms20150310
More informationSynopsis for study HAV-112 EXT M210 (110678)
Synopsis for study HAV-112 EXT M210 (110678) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full
More informationNorfolk and Norwich Simple Hepatitis B Vaccination and Surveillance Guide
Norfolk and Norwich Simple Hepatitis B Vaccination and Surveillance Guide (Don t immunise patients if HBsAg +ve ) CONTENT 1. Context, 2. Purpose and Scope, 3. Patient selection criteria, 4. Patient exclusion
More informationSeroprevalence of HAV among Male patients living with HBV at four private hospitals in Southwestern Nigeria
Int.J.Curr.Microbiol.App.Sci (216) 5(3): 226-23 International Journal of Current Microbiology and Applied Sciences ISSN: 2319-776 Volume 5 Number 3(216) pp. 226-23 Journal homepage: http://www.ijcmas.com
More informationEpidemiology Update Hepatitis A
December 2011 Epidemiology Update Hepatitis A Hepatitis A Key Points Between 2000 and 2010, 209 cases of hepatitis A were reported in Hennepin County residents. This represents 30% of the cases reported
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHepatitis B vaccination in Haemodialysis Patients: The Impact of Local Endemicity
1 Hepatitis B vaccination in Haemodialysis Patients: The Impact of Local Endemicity Dr. Salwa Ibrahim, MD MRCP Assistant Professor of Nephrology Cairo University, Egypt Patients on hemodialysis therapy
More informationAssessment of Immunization Rate of Hepatitis B Vaccination among Health Care Personnel in Tehran
Govaresh/ Vol. 9, No. 4, Winter 2004; 266-271 Assessment of Immunization Rate of Hepatitis B Vaccination among Health Care Personnel in Tehran Javad Mikaeli 1, Masoud Reza Sohrabi 2, Behrooz Ziad Alizadeh
More informationThe University of Toledo Medical Center and its Medical Staff, Residents, Fellows, Salaried and Hourly employees
Name of Policy: Policy Number: Department: Approving Officer: Responsible Agent: Scope: Healthcare Worker Immunizations 3364-109-EH-603 Infection Prevention and Control Hospital Administration Medical
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures, which have been finalised before approval of AMBIRIX. This scientific discussion has
More informationHepatitis B (HBV) vaccine: need for a booster injection? VHPB, Kyiv 2004
Hepatitis B (HBV) vaccine: need for a booster injection? VHPB, Kyiv 2004 Information for the Development of Immunization Policy 2002 update (WHO/V&B/02.28, printed: March 2003) The priorities for hepatitis
More informationHepatitis B Vaccination among Physicians, Dentists and Nurses in Bahrain
Bahrain Medical Bulletin, Vol. 35, No. 4, December 2013 Hepatitis B Vaccination among Physicians, Dentists and Nurses in Bahrain Sameer Abdulla Al-Haddad, MD, ABFM, MSc* Jaleela S Jawad, MD, ABFM, MSc**
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTo provide the guidelines for the management of healthcare workers who have had an occupational exposure to blood and/or body fluids.
TITLE/DESCRIPTION: MANAGEMENT OF OCCUPATIONAL EXPOSURE TO HBV, HCV, and HIV INDEX NUMBER: EFFECTIVE DATE: APPLIES TO: ISSUING AUTHORITY: 01/01/2009 01/01/2013 All GCC Countries GULF COOPERATION COUNCIL
More informationMA PERINATAL HEPATITIS B PREVENTION PROGRAM
MA PERINATAL HEPATITIS B PREVENTION PROGRAM Massachusetts Department of Public Health Immunization Program MIAP 2016 1 1 Presenter Disclosure Information I, Theodora Wohler, have been asked to disclose
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRoutine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002
Routine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002 Ann R. Fingar, MD, MPH, and Byron J. Francis, MD, MPH Burden of suffering Vaccines are available
More informationUpdate: ACIP Recommendations for Hepatitis B Vaccination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Update: ACIP Recommendations for Hepatitis B Vaccination Sarah Schillie, MD, MPH, MBA Summit for the Elimination of Hepatitis B and
More informationLONG-TERM PROTECTIVE RABIES ANTIBODIES IN THAI CHILDREN AFTER PRE-EXPOSURE RABIES VACCINATION
LONG-TERM PROTECTIVE RABIES ANTIBODIES IN THAI CHILDREN AFTER PRE-EXPOSURE RABIES VACCINATION Supawat Chatchen, Shakil Ibrahim, Pataporn Wisetsing and Kriengsak Limkittikul Department of Tropical Pediatrics,
More informationLong-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationObservational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children Hilton Whittle, Shabbar Jaffar, Michael Wansbrough, Maimuna Mendy, Uga Dumpis, Andrew Collinson,
More informationIs Any Factor Influence On Hepatitis B Vaccination Response In Hemodialysis Patients?
ISPUB.COM The Internet Journal of Nephrology Volume 3 Number 2 Is Any Factor Influence On Hepatitis B Vaccination Response In Hemodialysis Patients? A Ramezani, A Eslami far, F Ahmadi, S Maziar, E Razeghi,
More informationHepatitis B vaccination worldwide: Lessons learnt and the way forward
Hepatitis B vaccination worldwide: Lessons learnt and the way forward VHPB Russia meeting Oct 2018 Pierre Van Damme MD, PhD History Hepatitis B vaccines have been available since early 1980 s First recommended
More informationHBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board
HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: XX/XXXX
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TWINRIX safely and effectively. See full prescribing information for TWINRIX. TWINRIX [Hepatitis
More informationDownloaded from:
Whittle, H; Jaffar, S; Wansbrough, M; Mendy, M; Dumpis, U; Collinson, A; Hall, A (22) Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ, 325
More informationAlthough hepatitis A virus (HAV) infection is. Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal ) in the Elderly
78 Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal ) in the Elderly Valérie D Acremont, MD, DTM&H, * Christian Herzog, MD, DTM&H, and Blaise Genton, MD, PhD, DTM&H * * Medical Outpatient
More informationEvaluation of hepatitis B vaccine responsiveness in hemodialysis and peritoneal dialysis patients
International Journal of Research in Medical Sciences Farag SE et al. Int J Res Med Sci. 2015 Sep;3(9):2259-2263 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20150613
More informationPersistence of Immunity to Live Attenuated Varicella Vaccine in Healthy Adults
MAJOR ARTICLE Persistence of Immunity to Live Attenuated Varicella Vaccine in Healthy Adults Krow Ampofo, 1 Lisa Saiman, 1,2 Philip LaRussa, 1 Sharon Steinberg, 1 Paula Annunziato, 1 and Anne Gershon 1
More information注 : 第 3 页黑体加浓部分 Postgraduate Medical Journal 2002;78: The Fellowship of Postgraduate Medicine
注 : 第 3 页黑体加浓部分 Postgraduate Medical Journal 2002;78:538-540 2002 The Fellowship of Postgraduate Medicine ORIGINAL ARTICLE Vaccination against hepatitis B infection in patients with end stage renal disease
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCUSOM Student Health Immunization Requirements
CUSOM Student Health Immunization Requirements Regulatory and legislative authorities require that students demonstrate immunization, immunity and/or protection from multiple contagious diseases before
More informationVHPB Meeting, Israel Prof Shmuel Rishpon Head of the Advisory Committee on infectious diseases and Immunization Ministry of Health Israel
VHPB Meeting, Israel Prof Shmuel Rishpon Head of the Advisory Committee on infectious diseases and Immunization Ministry of Health Israel Yad Hashmona, 15.3.13 1 Immunization policy in Israel Immunization
More informationAnalysis of immunogenicity
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOriginal. Article. Immune Response Rate after Viral Hepatitis B Immunization in Chronic Liver Disease Patients. Prasomsree K Boonsirichan R ABSTRACT
THAI J 80 GASTROENTEROL Original Article Immune Response Rate after Viral Hepatitis B Immunization in Chronic Liver Prasomsree K Boonsirichan R ABSTRACT Background: Vaccination against hepatitis B infection
More informationVIRAL HEPATITIS. Monique Punsalan Angelie Regala James Rondal
VIRAL HEPATITIS Monique Punsalan Angelie Regala James Rondal PRIMARY VIRAL HEPATITIS INCUBATION (DAYS) HEPATITIS A HEPATITIS B HEPATITIS C HEPATITIS D HEPATITITS E 15-45, MEAN 30 30-180, MEAN 60-90 15-160,
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationLong term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers
Archives of Disease in Childhood 1997;77:F47 F51 F47 Viral Hepatitis Research Unit Chulalongkorn University Hospital, Bangkok, Thailand Y Poovorawan Department of Paediatrics S Sanpavat S Chumdermpadetsuk
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationVACCINATING HIV+ ADULTS
OLIVER KOCH VACCINATING HIV+ ADULTS BHIVA VACCINATION GUIDELINES (2015) VACCINATION IN THE REAL WORLD VACCINATION - THE DEBATE CONTINUES OR OR VACCINATION IS A BARBAROUS PRACTICE, AND IT IS ONE OF THE
More informationDisclosures. I have no financial interests in immunizations discussed here. I may discuss off-label use of licensed vaccines
2/28/18 Disclosures I have no financial interests in immunizations discussed here I may discuss off-label use of licensed vaccines Herpes Zoster (HZ) and Postherpetic Neuralgia (PHN) epidemiology, United
More informationA Double-Dose Hepatitis B Vaccination Schedule in Travelers Presenting for Late Consultation
I S T M 260 ORIGINAL ARTICLE A Double-Dose Hepatitis B Vaccination Schedule in Travelers Presenting for Late Consultation Jason Wong, MD, Michael Payne, MD, and Susan Hollenberg, MD School of Population
More informationTWINRIX GlaxoSmithKline
TWINRIX GlaxoSmithKline 1. Name of medicinal product Twinrix 2. Qualitative and quantitative composition Twinrix is a combined vaccine formulated by pooling bulk preparations of the purified, inactivated
More informationA scoring system for the effectiveness of Hepatitis-B vaccination in children receiving treatment for cancer
Turkish Journal of Cancer Vol.3/ No. 4/2 A scoring system for the effectiveness of Hepatitis-B vaccination in children receiving treatment for cancer FUNDA ÇORAPÇIOĞLU, FAİK SARIALİOĞLU, NUR OLGUN, KAMER
More informationChing-Wen Wang, Li-Chieh Wang, Mei-Hwei Chang,* Yen-Hsuan Ni, Huey-Ling Chen, Hong-Yuan Hsu, and Ding-Shin Chen
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Dec. 2005, p. 1442 1447 Vol. 12, No. 12 1071-412X/05/$08.00 0 doi:10.1128/cdli.12.12.1442 1447.2005 Copyright 2005, American Society for Microbiology. All
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationRapid seroprotection against hepatitis B following the rst dose of a Pre-S 1 /Pre-S 2 /S vaccine
Journal of Hepatology 34 (2001) 123±127 www.elsevier.com/locate/jhep Rapid seroprotection against hepatitis B following the rst dose of a Pre-S 1 /Pre-S 2 /S vaccine Michael Y. Shapira 1, Evelyn Zeira
More informationPrevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy
Vaccine 24 (2006) 3095 3099 Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy Sudawan Siriaksorn a, Thanyawee
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTo demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUniversal hepatitis B (HB) immunization has
Determination of Immune Memory to Hepatitis B Vaccination Through Early Booster Response in College Students Chyi-Feng Jan, 1,2 Kuo-Chin Huang, 1 Yin-Chu Chien, 3 Donald E. Greydanus, 2 H. Dele Davies,
More informationOriginal Article. Hepatitis B Infection: Prevalence and Response to Vaccination among Health Care Workers in Babol, Northern Iran
Iranian Journal of Pathology (2014) 9 (3), 187-192 187 Original Article Hepatitis B Infection: Prevalence and Response to Vaccination among Health Care Workers in Babol, Northern Iran Masomeh Bayani 1,
More informationKey words:hepatitis B vaccine,anti-hbs,cellular immunity,side effect
Key words:hepatitis B vaccine,anti-hbs,cellular immunity,side effect Table 1 Age and sex of the vaccinees given H-B-VAX male and female vaccinees given H-B-VAX. Fig.1 Comparison of anti-hbs development
More information